Vibrant

Quick links to important sections

Vibrant

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vibrant

What is Vibrant? A Foundational Overview

Property Description
Active Ingredients Diclofenac Diethylammonium, Linseed Oil, Menthol, Methyl Salicylate
Form Gel (Emulgel), Topical preparation
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID) and Topical Analgesic/Counterirritant
General Purpose Localized relief of musculoskeletal pain and inflammation
Origin Combination of synthetic and natural compounds

What Type of Medicine is Vibrant?

Vibrant is classified as a multicomponent topical preparation used for localized relief, functioning primarily as a Topical Analgesic that incorporates a Nonsteroidal Anti-Inflammatory Drug (NSAID). This combination product, formulated as a gel (emulgel), is designed for topical (dermal) application directly onto the skin. The medicine is commonly available over-the-counter (OTC) for patient accessibility. The Diclofenac component, in the form of Diclofenac Diethylammonium, is a well-established agent in pain management, recognized for its anti-inflammatory action. This means the core ingredient directly helps to soothe the biological swelling and irritation.


Composition: Synthetic NSAID and Natural Counterirritants

The efficacy of Vibrant is derived from four distinct active ingredients: Diclofenac Diethylammonium, Methyl Salicylate, Menthol, and Linseed Oil (Oleum Lini). The formulation is an intermix of both synthetic and natural compounds. Diclofenac Diethylammonium is the key synthetic component, providing the anti-inflammatory action of the NSAID class. Complementing this are Methyl Salicylate and Menthol, which are classified as external analgesics and counterirritants. This means these ingredients work by creating an immediate cooling sensation and diverting attention from deeper pain. Linseed Oil is also incorporated into the emulgel base, giving the product a distinct non-greasy texture and potentially contributing to the overall therapeutic profile.


What is Vibrant's General Purpose?

The primary purpose of Vibrant is to provide targeted, localized relief for musculoskeletal pain and localized inflammatory conditions. By combining an established NSAID with powerful counterirritants, the preparation delivers a dual mechanism of effect: it helps reduce the biological processes that cause inflammation, while simultaneously offering an immediate analgesic effect on the skin's surface. This approach is beneficial for patients managing localized aches and pains, such as those associated with common occurrences like a strained knee after physical activity or soft tissue injury in the shoulder. The unique emulgel form facilitates better absorption into the deeper tissues compared to standard creams.

Regulatory References

  1. Nonsteroidal Anti-Inflammatory Drug (NSAID)
  2. musculoskeletal pain
  3. anti-inflammatory action

What side effects are possible with Vibrant?

Possible Side Effects and Safety Information

The safety profile for this topical preparation is derived from regulatory documentation for its active components, primarily the non-steroidal anti-inflammatory drug (NSAID) diclofenac diethylamine.


Adverse Reactions and Frequency Classification

The most frequently documented side effects are localized skin reactions at the application site, classified by regulators based on estimated frequency:

Frequency Classification Affected System-Organ Class Common Adverse Reactions
Common (ge 1/100 to <1/10) Skin and Subcutaneous Tissue Disorders Dermatitis (including contact dermatitis), skin rash, erythema (redness), eczema, pruritus (itching)
Very Rare (<1/10,000) Immune System Disorders Hypersensitivity (including urticaria, angioedema)
Very Rare (<1/10,000) Skin and Subcutaneous Tissue Disorders Photosensitivity reaction, pustular rash

Serious Adverse Reactions and Systemic Risk

Although systemic absorption is typically low, official labeling notes that the possibility of systemic adverse effects cannot be excluded, especially when the product is applied to large areas or for a prolonged period. The serious risks associated with the NSAID class include:

  • Cardiovascular Thrombotic Events: Potential for serious events such as myocardial infarction and stroke.
  • Gastrointestinal Effects: Risk of serious gastrointestinal events, including bleeding, ulceration, and perforation.
  • Severe Skin Reactions: Rare but severe reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Population-Specific Safety Constraints

Regulatory documents define strict limitations for specific populations:

  • Pregnancy: Contraindicated during the third trimester. Use in the first and second trimesters is discouraged unless clearly necessary.
  • Children and Adolescents: Contraindicated in individuals under 14 years of age.
  • Allergy History: Contraindicated in patients who have experienced asthma, acute rhinitis, or urticaria after taking aspirin or other NSAIDs.
  • Surgical Risk: Contraindicated in the setting of Coronary Artery Bypass Grafting (CABG) surgery.
  • Application Constraints: The gel must not be used on open wounds, damaged skin, or with an airtight occlusive dressing.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of this topical gel is considered extremely unlikely with normal use due to the low systemic absorption of the active ingredients. The official regulatory profile primarily addresses the risk associated with accidental ingestion, which may lead to systemic effects similar to an overdose of oral Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).


Documented Overdose Presentations and Risks

If accidental ingestion occurs, manifestations may include gastrointestinal irritation (nausea, vomiting, epigastric pain), hypotension, and convulsions. More serious potential outcomes documented for systemic NSAID toxicity include serious cardiovascular thrombotic events (such as stroke or myocardial infarction) and severe gastrointestinal adverse events (including bleeding, ulceration, or perforation).


Emergency Actions and Management

Immediate medical attention must be sought if symptoms of a severe systemic event are experienced, including chest pain, sudden weakness, slurred speech, or signs of an anaphylactic reaction.

Management is focused on supportive and symptomatic measures for complications like renal failure or respiratory depression, as no specific antidote is known for Diclofenac overdosage. Caution is advised for accidental ingestion in the elderly and those with reduced cardiac, hepatic, or renal function. The product is contraindicated during the third trimester of pregnancy due to systemic risks.

Therapeutic Uses of Vibrant

Main Uses and Benefits of Vibrant

Vibrant is a non-pharmacological capsule designed to support the management of chronic idiopathic constipation in adults who have not achieved adequate relief from lifestyle changes or laxative therapies. Unlike chemical treatments, this technology utilizes mechanical stimulation to address symptoms.

Primary Mechanism and Use

The primary use of Vibrant is to promote bowel movements by addressing the body's natural circadian rhythm. The capsule is ingested and travels through the digestive tract to the colon, where it delivers programmed micro-vibrations. These mechanical pulses are intended to stimulate the enteric nervous system, helping to increase the frequency of spontaneous bowel movements.

Benefits in Chronic Constipation

The benefits of this therapy focus on improving the physiological aspects of colonic transit and enhancing the quality of life for individuals with persistent constipation. Key benefits observed include:

  • Increased Bowel Movement Frequency: Helping patients achieve a higher number of complete spontaneous bowel movements per week.
  • Improvement in Stool Consistency: Facilitating easier passage by assisting the natural motility of the colon.
  • Reduction in Straining: By promoting regular movement, the therapy may help decrease the physical effort required during elimination.
  • Non-Drug Approach: As a mechanical treatment, it provides an alternative for those who prefer to avoid systemic medications or who experience insufficient results from traditional laxatives.

Treatment Goals

The goal of using Vibrant is to restore a more regular rhythm to the digestive system. By augmenting the natural contractions of the colon, the treatment aims to provide a predictable and consistent management strategy for chronic constipation symptoms without the use of chemicals or stimulants.

Regulatory References

  1. TMDA Summary of Product Characteristics (SmPC) for a similar gel

Eligibility and Restrictions for Use

The use of the Vibrant System is strictly defined by regulatory eligibility criteria, primarily restricting use to adults (age 18 and older) diagnosed with Chronic Idiopathic Constipation (CIC) who have not found relief from standard laxative therapies for at least one month.


Contraindications and Prohibited Use

Vibrant is contraindicated (must not be used) in patients with specific clinical conditions or physiological states to prevent potential complications. These prohibitions are mandated in the official labeling:

  • Gastrointestinal Obstruction: A history of or suspected intestinal or colonic obstruction, or complicated/obstructive diverticular disease.
  • Significant GI Disorders: History of significant gastroparesis, inflammatory bowel disease (IBD), gastrointestinal malignancy, anal fissures, or fistulas.
  • Esophageal Conditions: History of Zenker’s diverticulum, dysphagia (trouble swallowing), esophageal stricture, eosinophilic esophagitis, or achalasia.
  • Special Populations: Women who are pregnant or lactating (breastfeeding).

Eligibility-Related Restrictions

Classification Regulatory Statement
Age Restriction Use is restricted to adults; safety and effectiveness in pediatric patients have not been established.
Device Compatibility Must not be used by patients with implanted electrical devices (e.g., pacemakers) or who require an immediate MRI, as the capsule is magnetic resonance unsafe until expelled.

What should I know about interactions with other medicines?

The official regulatory profile for Vibrant is defined by interactions primarily stemming from the systemic exposure of its Diclofenac (NSAID) component. The most significant documented risk is an additive bleeding risk, which occurs with co-administration of agents that interfere with hemostasis, including Anticoagulants (such as Warfarin), Antiplatelet Agents, SSRIs, and SNRIs.

Regulatory documentation also describes pharmacodynamic interactions that affect cardiovascular drugs, stating that the NSAID component may diminish the antihypertensive effect of ACE Inhibitors, ARBs, and Beta-Blockers, and reduce the natriuretic effect of Diuretics. This combination is noted to pose a risk of deterioration of renal function in the elderly or in patients with pre-existing renal impairment.

Official interaction statements specify several critical constraints:

  • Oral NSAIDs are an officially restricted or avoided combination due to the potential for increased systemic adverse effects.
  • Co-use with substances like Methotrexate or Digoxin may increase the serum concentration of those drugs.
  • The use of the gel with other topical products on the same site has not been evaluated by regulators and should be avoided.
  • Consumption of alcohol is associated with an increased potential for gastrointestinal blood loss.

Mechanism of Action

Dual Mechanism of Action: Causal and Sensory Modulation

Vibrant operates through two distinct, complementary mechanistic domains to modulate local physiological responses. The core action involves enzyme inhibition by targeting the biochemical pathways initiating the inflammatory response, while simultaneously utilizing sensory signaling modulation to alter sensory afferent transmission. This strategy engages both the Arachidonic Acid Cascade and the Peripheral Nociceptive Signaling Pathway at the application site.


Inhibiting the Inflammatory Mediator Cascade

The mechanism involving diclofenac is executed through non-selective competitive inhibition of the Cyclooxygenase (COX) enzymes. By blocking the conversion of arachidonic acid, the mechanism severely limits the local synthesis of prostaglandins—key mediators that trigger vasodilation and sensitize peripheral fibers. This effect modulates the molecular pathways driving localized inflammatory responses, resulting in diminished peripheral sensitization of nociceptors.


Modulating Nociceptive Signals via Sensory Agonism

The mechanism involves rapid TRPM8 ion channel activation by counterirritant components, menthol and methyl salicylate. Menthol acts as an agonist of the TRPM8 ion channel located on peripheral sensory neurons, causing rapid depolarization. This sensory activation generates a strong, competing afferent signal that alters local sensory processing. This engagement of the nociceptive signaling pathway modulates the signaling output of local sensory afferents.

Dosage and Administration Information

How to Use Vibrant

Vibrant is a multicomponent topical analgesic gel designated for cutaneous (dermal) application only, with its use strictly defined by guidelines concerning quantity, frequency, and duration. This product is not intended for oral consumption or application to mucous membranes.


Standard Administration Parameters

Instruction Domain Official Guidelines
Administration Route Topical (Dermal) application to the skin surface.
Standard Dosing The prescribed amount must be measured precisely using the dosing card provided with the product. Dosing varies by site: 2 grams for upper extremities and 4 grams for lower extremities, not to exceed 32 grams total per day.
Frequency Pattern The gel is applied to the affected area four times daily. If a dose is missed, the subsequent application should be made at the regularly scheduled time.
Application Method The measured gel must be gently rubbed into the skin until fully absorbed. Hands must be washed completely immediately after application, unless the hands are the site of treatment.
Duration of Use Use is typically defined as a short-term course for acute conditions. For soft tissue injuries, the duration should generally not exceed 14 days without reassessment.

High-Level Usage Constraints

Guidelines specify that the gel must not be applied to skin with open wounds, cuts, or infections. For the pediatric population (under 14 years), the use of this specific formulation is not recommended due to a lack of sufficient supporting usage data. These instructions structure the use of the medicine, dictating the precise topical approach and the short-term nature of administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Vibrant

Evidence for Acute Localized Soft Tissue Injuries (Sprains and Strains)

Research related to this type of topical preparation in sudden, localized soft tissue injuries, like a sprain or muscle strain, primarily comes from short-term Randomized Controlled Trials (RCTs) and subsequent large meta-analyses. These studies explored how symptoms change over time when the Diclofenac component was applied in the study setting. Researchers monitored measurements of patient-reported outcomes describing perceived discomfort, specifically examining Pain Intensity and Pain on Movement using standardized scales. Findings help contextualize how patients reported their experience when the topical formulation was applied compared to a non-medicated gel base (vehicle).

What remains uncertain is the specific contribution of the full four-component combination (including ingredients like Menthol and Linseed Oil) compared to the Diclofenac component alone. While the overall evidence base is relevant in trials assessing short-term symptom patterns, there is limited information on whether the additional components significantly alter the observed symptom patterns.


Evidence for Localized Chronic Musculoskeletal Conditions (Mild Osteoarthritis)

Studies have examined topical Diclofenac formulations in conditions characterized by fluctuating or episodic manifestations, such as mild, localized osteoarthritis of the knee or hand, involving trials of a mid-term duration, typically lasting 6 to 12 weeks. The outcomes monitored included measurements of OA Pain (at rest and with activity), along with functional metrics like reported Joint Stiffness and measures of Physical Function over the mid-term.

Data specifically concerning the long-term use (beyond three months) of this exact four-component combination for managing chronic discomfort are not fully established. The existing evidence is largely derived from research on single-component topical Diclofenac gels. Therefore, the role of the counterirritants and Linseed Oil in the context of extended, chronic management remains an area where targeted comparative evidence is not readily available.


Evidence in Specific Groups and Populations

Studies have evaluated topical Diclofenac formulations in certain specific populations, including adolescents (typically age 14 and over) experiencing acute, minor sports-related injuries, and older adults with localized, mild osteoarthritis. It is important to note that findings describe group patterns, and results apply only to the populations studied. Data for other groups, such as children under 14 or populations with specific comorbidities, remain insufficient within the high-quality randomized trial settings cited by regulators.

Key Studies & References

  1. Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022)

Frequently Asked Questions (FAQ)

Common questions about Vibrant (FAQ)

Q: Has Vibrant been approved by the FDA (or equivalent international body)?

The medicine has undergone regulatory review and is approved for its specific uses by major governmental bodies. Official product documentation frequently references materials such as the FDA Prescribing Information and the MHRA Summary of Product Characteristics (SmPC). Official documentation confirms that the product's safety and efficacy have been reviewed by regulatory authorities.

Q: What does 'contraindication' mean for Vibrant?

A contraindication is a clinical condition or factor that prevents the use of a medicine because the potential harm would outweigh any possible benefit. For Vibrant, official labeling lists specific medical conditions, age restrictions, and physiological states (like the third trimester of pregnancy) that prohibit its use. This term is used to define mandatory safety exclusions in the regulatory document.

Q: What type of healthcare provider can prescribe Vibrant?

Vibrant is commonly available as an Over-the-Counter (OTC) medicine, meaning a prescription may not be necessary. When a prescription is used, it can be written by any licensed healthcare professional with prescriptive authority (e.g., a doctor, physician assistant, or nurse practitioner).

Q: Is Vibrant addictive or habit-forming?

According to official regulatory documentation and classification standards, Vibrant is not categorized as a controlled substance. The active components are not known to lead to physical dependence. Therefore, the product is not considered addictive or habit-forming.

Q: Is there a risk of withdrawal symptoms if Vibrant is stopped abruptly?

Vibrant is a topical analgesic and is not associated with physical dependence. Therefore, there are no documented withdrawal symptoms associated with the abrupt cessation of this product in regulatory labeling.

Q: What should I do if the expected effects of Vibrant do not seem to happen?

Official regulatory guidance, such as the Summary of Product Characteristics (SmPC), typically defines a maximum duration of use for acute conditions (e.g., 14 days). If expected benefits are not observed within the recommended time frame, re-evaluation by a healthcare professional may be necessary to assess the condition and treatment plan.

Q: How do people usually feel when they first start taking Vibrant?

The product is designed with a dual mechanism of action, which includes counterirritant components like menthol and methyl salicylate. These ingredients are intended to produce a localized cooling sensation immediately upon application. This sensory activation may offer an immediate, competing signal that distracts from the deeper pain.

Q: Are there any food restrictions while taking Vibrant?

Official regulatory documents do not specify any general food restrictions for this topical medicine. The only intake-related warning concerns alcohol consumption. Co-use of alcohol may increase the potential for gastrointestinal blood loss due to the systemic effects of the NSAID component.

Q: Is Vibrant safe to take with common vitamins or supplements?

Regulatory documentation on drug interactions is generally limited to other medicines and does not provide specific data on common vitamins or general supplements. Because Vibrant contains an NSAID component, the potential for interaction, particularly with systemic supplements that affect bleeding risk, should be considered. All concurrent supplements should be disclosed to a healthcare provider.

Q: Does Vibrant affect kidney or liver function?

As with all medicines containing an NSAID, the possibility of systemic adverse effects on major organs exists, especially with prolonged or excessive use. Regulatory documents note that the possibility of serious effects on kidney function and, less commonly, liver function cannot be excluded. The presence of pre-existing organ impairment is noted as a risk factor.

Q: Do I need to get blood tests while I am taking Vibrant?

Regulatory labeling does not mandate routine monitoring tests for the general population using the topical gel. However, the decision regarding blood tests rests with the prescribing physician. Specific monitoring may be considered for patients with pre-existing kidney conditions, those applying the gel to large skin areas, or those taking interacting medications.

Q: If I have a mild reaction, should I stop taking Vibrant immediately?

Official labeling mandates immediate discontinuation and medical attention for signs of a severe allergic reaction, such as swelling of the face or difficulty breathing. For common, mild, localized skin reactions (like redness or a rash), consultation with a healthcare professional is generally recommended before making changes to the prescribed use.

Q: Can I drive or operate machinery while taking Vibrant?

Due to the typically low systemic absorption of the topical gel, official labeling does not mandate a specific blanket warning against driving or operating heavy machinery. The potential for rare systemic side effects, such as dizziness or blurred vision, should be considered.

Q: Does Vibrant cause fatigue or trouble sleeping?

The most frequently reported side effects are localized skin reactions at the application site, such as redness or itching. According to official product information, systemic (whole-body) side effects like fatigue or trouble sleeping (insomnia) are reported as very rare when the NSAID component is absorbed. The low systemic absorption associated with topical use may reduce the risk of these effects compared to oral NSAIDs.

Q: Is it normal to feel a change in appetite with Vibrant?

Changes in appetite are not listed as a common or frequently observed side effect in the regulatory documentation for this topical NSAID formulation. Side effects that occur outside of the common localized skin reactions are typically categorized as very rare.

Q: Is Vibrant known to cause weight gain?

According to official regulatory labeling, weight gain is not listed as a common or frequent adverse reaction associated with this topical NSAID formulation. Reported side effects are primarily localized skin reactions. Weight changes are not typical reactions and would require evaluation by a healthcare professional.

Q: Does Vibrant affect mood or energy levels?

Effects on mood or energy levels are not listed as common or frequent side effects in the official documentation for this topical NSAID formulation. The medicine is primarily designed for localized action at the application site.

Q: How long do the effects of Vibrant last after stopping the medication?

The active NSAID component is administered topically and has a relatively short half-life in the bloodstream. The localized therapeutic effect (pain and inflammation modulation) is generally expected to diminish shortly after the prescribed course of medication is completed.

Q: Is there a generic version of Vibrant available?

The availability of an approved generic version is a matter of public record maintained by government drug regulatory bodies. Since Vibrant is a combination product, generic status is determined by the specific ingredients and formulation. This information is available in official drug databases, such as the FDA Orange Book.

How should Vibrant be stored and disposed of?

How to Store and Dispose of Vibrant?

Vibrant (diclofenac diethylammonium topical gel) must be stored strictly according to official regulatory guidelines to maintain its stability.


Storage Requirements

Detail Official Regulatory Requirement
Temperature Store at Controlled Room Temperature, typically below 30, C (86, F); do not freeze.
Protection Protect from heat; keep the product in the original container with the tube tightly closed.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired gel must not be disposed of in household trash or poured into the sink or drains, as it poses a risk to the aquatic environment. Instead, dispose of the medicine and any waste material through an authorized pharmacy take-back scheme or according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Vibrant found in:

A-Z Index: